Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Pesampator in Healthy Volunteers
NCT02228395Phase 1Completed
- Sponsor
- Biogen
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pesampator in schizophrenia (3 cohorts), sponsored by Biogen. Primary endpoints: Columbia Suicide Severity Rating Scale, Treatment-Emergent Adverse Events and Serious Adverse Events and 5 more. Started Sep 2014; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02228395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228395.